Wikipedia

Platelet-rich plasma

(Redirected from Autologous Conditioned Plasma)

Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of plasma protein derived from whole blood, centrifuged to remove red blood cells but retaining platelets. Though promoted for treating various medical conditions, evidence of its benefits was mixed as of 2020, showing effectiveness in certain conditions and ineffectiveness in others.[1][2][3]

Platelet-rich plasma
Platelet-rich plasma injection into the hand
MeSHD053657

As a concentrated source of blood plasma and autologous conditioned plasma, PRP contains multiple growth factors and other cytokines that can stimulate the healing of soft tissues and joints. Indications for its use include sports medicine and orthopaedics (such as acute muscle strains, tendinopathy,tendinosis, muscle-fascial injuries, and osteoarthritis,[4]) dermatology (for androgenic alopecia, wound healing, and skin rejuvenation), and even proctology (for fistula en ano[5]).[6]

Various preparation protocols exist, with the underlying principle of concentrating platelets to 3–5 times physiological levels, then injecting this concentrate into the tissue where healing is desired.[7] Beyond clinical practice, PRP has been utilized in various tissue engineering applications involving bone, cartilage, skin, and soft tissue repair. It serves as a source for the delivery of growth factors and/or cells within tissue-engineered constructs, often in combination with biomaterials. [8]

Medical use

edit

Evidence for benefit of PRP is mixed, with some evidence for use in certain conditions and against use in other conditions.[9][10][3] It has been investigated for chronic tendinitis,[11] osteoarthritis,[12] in oral surgery,[13] and in plastic surgery.[14]

Elbow tendinitis

edit

A 2022 study from the Journal of Clinical Medicine compared PRP injections to physical therapy. They found that PRP significantly lowered pain scores and increased elbow function.[15] A 2022 study considered PRP for elbow tendinopathy. They found that PRP was effective and that the concentration of the platelets and healing factors such as epidermal growth factor (EGF) were correlated with success of treatment.[16]

A 2022 meta-analysis reviewed 26 studies on PRP for elbow tendinopathy. They found that PRP-treated patients rated their results significantly better using validated patient rated outcomes measures.[17] A 2021 systematic review by the Cochrane Library examined PRP and autologous whole blood injections and concluded that it was "uncertain" if PRP or autologous whole blood injections improved elbow tendon healing.[18]

A 2018 systematic review and meta-analysis of high quality studies found that PRP was beneficial for treatment of lateral epicondylitis.[19]

Numerous reviews and meta-analyses have found that for elbow tendinopathy, PRP is superior to cortisone injections.[20][21][22][23][24] It has been shown to have similar[25] or equal[26][27] effects compared to surgery.

Rotator cuff disease

edit

A 2022 review and meta-analysis showed improved patient-rated outcomes in patients with partial rotator cuff tears. At 8 weeks post injection, they found PRP to be effective.[28] A 2021 prospective study examined the effectiveness of PRP for partial thickness rotator cuff tears. Patients were given 2 separate PRP injections and followed for 2 years. The study noted: “No adverse events were seen in any patient. Based on global rating scores positive results were seen in 77.9 % of patients at 6 months, 71.6 % at 1 year, and 68.8 % of patients at 2 years”. They found PRP most effective in more damaged tendons.[29] A 2021 meta-analysis found that PRP was effective for partial rotator cuff tears but the effects were no longer evident at 1 year.[30]

PRP has been shown to be superior to cortisone injections in several studies.[31] This is especially evident in the longer term.[32][33]

A 2019 review found it not to be useful in rotator cuff disease.[3] A 2018 review found that it may be useful.[19] A 2009 review found few randomized controlled trials that adequately evaluated the safety and efficacy of PRP treatments and concluded that PRP was "a promising, but not proven, treatment option for joint, tendon, ligament, and muscle injuries".[34]

Osteoarthritis

edit

Tentative evidence supports the use of PRP in osteoarthritis of the knee.[35][36] A 2019 meta-analysis found that PRP might be more effective in reducing pain and improving function than hyaluronic acid in knee arthritis.[37]

Meniscus injury

edit

A 2022 review found that in people with meniscus tears, PRP treatment reduced the failure rate of meniscus repair surgery and reduced postoperative pain. However, the review did not find consistent evidence that PRP improved knee function.[38]

Dental

edit

Platelet-rich plasma (PRP) is an emerging technique in tissue regeneration, increasingly used to enhance healing in dental and oral surgery, particularly for aging patients. PRP is derived from the patient's blood through centrifugation, concentrating growth factors that are crucial for wound healing and tissue repair.

Tooth Extractions and Periodontal Surgery: PRP application in the alveolar socket after tooth extractions improves soft tissue healing and positively affects bone regeneration, although the effect on bone tends to diminish after a few days. In periodontal therapy, PRP yields better results when combined with other materials compared to its use alone.

Implant Surgery: PRP has shown promising outcomes when used as a coating material in implant procedures, enhancing the healing process.

Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): Combining necrotic bone curettage with PRP application has been effective for treating refractory BRONJ, offering successful outcomes with minimal invasiveness. [39]

Other musculoskeletal

edit

A 2014 Cochrane review of musculoskeletal injuries found very weak evidence for a decrease in pain in the short term, and no difference in function in the short, medium or long term. It has not been shown to be useful for bone healing.[40] A 2016 review of bone graft augmentation found only one study reporting a difference in bone augmentation, while four studies found no difference.[41] As compared to other conservative treatments for non-surgical orthopedic illnesses (e.g. steroid injection for plantar fasciitis), evidence does not support the use of PRP as a conservative treatment.[42] A 2018 review found that evidence was lacking for Achilles tendinopathy.[43] A 2019 meta-analysis found that, for most outcomes in Achilles tendinopathy, PRP treatment did not differ from placebo treatment.[44] A 2019 study conducted an umbrella review that "considered studies that included populations with differing levels of physical activity, including studies on the sporting population (professional and/or recreational athletes) and studies didn't explicitly mention involving a sporting population." This inquiry reported only poor quality evidence that PRP offers any clinical benefits for treatment in acute muscle, tendon, and ligament injuries in any population.[45]

Hair loss

edit

Studies have reported that PRP is beneficial for alopecia areata[46] and androgenetic alopecia and can be used as an alternative to minoxidil or finasteride.[47] A review reported it to improve hair density and thickness in both genders.[48] A minimum of 3 treatments, once a month for 3 months are recommended, and afterwards a 3-6 month period of continual appointments for maintenance.[49] Factors that determine efficacy include number of sessions, double versus single centrifugation, age and gender, and where insertion site.[50]

Assisted reproduction

edit

PRP can be inoculated into the uterine cavity, to improve endometrial receptivity in cases of refractory endometrium. Studies have reported that intrauterine inoculation of PRP before embryo transfer can thicken the endometrium and improve reproductive prognosis.[51] PRP has been studied for the management of Asherman's Syndrome.[52]

PRP can be inoculated experimentally into the ovary to promote ovarian tissue regeneration. The main applications would be in cases of diminished ovarian reserve or premature ovarian failure.[53]

A 2023 retrospective observational study reported PRP's effectiveness in rejuvenating ovarian fertility and viability in terms of "the influence of intraovarian injection of autologous PRP on the levels of E2".[53] and pregnancy outcome in women treated with PRP who had a history of infertility, hormonal abnormalities, an absence of menstrual cycle, and premature ovarian failure in a single centre."[53]

A 2024 review showed that PRP is beneficial when used as intraovarian injections for women with decreased fertility. PRP used for fertility trouble increases AFC,[54] number of cleavage embryos, and improves cancellation rate in women with poor ovarian reserve. However, "Although there was an improvement of baseline hormones (anti-Müllerian hormone, follicle-stimulating hormone, and estradiol) after intraovarian injection of PRP, this improvement failed to reach statistical significance (except the improvement of serum AMH analyzed in quasi-experimental studies)."[55]

Venous ulcers

edit

Venous ulcers are persistent ankle or lower leg wounds that become open.[56] A 2024 meta-analysis reported a positive effect on the size of ulcers as well as complete healing time for venous ulcers compared to standard treatments. A study combining a PRP therapy with conventional venous ulcer treatments reported improved quality of life and healing time. "In terms of safety, the recurrence rate in the PRP group was significantly lower than that in the control group, while the rates of infection and irritative dermatitis showed no significant difference from the control group."[57]

Diabetic foot ulcers

edit

A 2024 meta-analysis reported that the growth factors present in PRP are vital in the healing of diabetic foot ulcers; specifically in their closure. The treatments were reported to significantly increase the healing rate in comparison to conventional treatments.[58]

Aesthetic medicine

edit

Platelet-rich plasma therapy is a minimally invasive procedure that may be used in aesthetic medicine to treat skin conditions such as the removal of wrinkles, the reduction of lines, and improvement of blemishes, and hair loss. Concentrated PRP solution is injected into the treatment area to target damaged cells and tissues. The growth factors and proteins in PRP aid in rejuvenating the skin, and improving the condition of the scalp stimulating hair growth.[59]

Adverse effects

edit

Adverse effects have been reported to be low in most trials. A review reported weak evidence of harm, occurring at comparable, low rates in treated and untreated people.[60][18]

Composition

edit
 
Whole blood placed in centrifuge prior to two-stage centrifugation

The three general categories of preparation of PRP based on leukocyte and fibrin content are leukocyte-rich PRP, leukocyte reduced PRP, and leukocyte platelet-rich fibrin.[7][61]

The efficacy of certain growth factors in healing various injuries and the concentrations of these growth factors found within PRP are the theoretical basis for the use of PRP in tissue repair.[62] Though not required for the process, platelets can be activated by the addition of thrombin or calcium chloride, which induce the release of the factors from alpha granules. The addition of thrombin or calcium chloride is not required as natural thrombin activates the cells upon injection. The growth factors and other cytokines present in PRP include:[62][63][64][65]

Manufacturing

edit

PRP is prepared by taking blood from the person, and then putting it through centrifugation designed to separate PRP from platelet-poor plasma and red blood cells. This is usually done in the clinic, using commercially available kits and equipment.[66] The resulting substance varies from person to person and from facility to facility.[66][67]

  •  
    Blood drawn from patient
  •  
    Removal of PRP after double centrifugation
  •  
    PRP is Injected into area of injury via ultrasound guidance

Regulatory status

edit

Use in an office setting is not approved by the FDA.[68]

Society and culture

edit

PRP has received attention in media[69][70][71] as a result of its use by athletes.[72]

In the 2010s, cosmetic procedures marketed under the name of "vampire facials" grew in popularity, fueled by celebrity endorsement. These facials generally center on PRP treatment, and usually involve microneedling.[73][74]

In April 2024, the CDC announced that three women who had been patients at the Albuquerque, New Mexico, VIP Spa had been diagnosed with HIV after getting such facials. Another almost 200 former clients and their sexual partners tested negative.[75]

PRP has been injected into the vagina, in a procedure called "O-shot[76]" or "orgasm shot", with claims to improve orgasms.[77] No evidence supports such claims.[77][78]

Doping

edit

PRP treatments may violate anti-doping rules.[62] As of 2010, it was not clear whether PRP could have a systemic impact on circulating cytokine levels, affecting doping tests and whether PRP treatments had systemic anabolic effects or affect performance.[62] In January 2011, the World Anti-Doping Agency removed intramuscular injections of PRP from its prohibitions after determining that there is a "lack of any current evidence concerning the use of these methods for purposes of performance enhancement".[79]

History

edit

In the early 1940s clinicians used extracts of growth factors and cytokines for healing. The term 'platet-rich plasma' was first used in 1954 by Kingsley and in the 1960s the first PRP blood banks were established, becoming popular by the 1970s.[80] In the 1970s PRP was used in hematology, originally for transfusions to treat thrombocytopenia. Ten years later it was used for maxillofacial surgeries.[6] PRP was first used in Italy in 1987 in an open heart surgery procedure.[81] In 2006 PRP was starting to be considered of potential use for both androgenic alopecia and alopecia areata.[6]

See also

edit

References

edit
  1. ^ Xu Q, Chen J, Cheng L (July 2019). "Comparison of platelet rich plasma and corticosteroids in the management of lateral epicondylitis: A meta-analysis of randomized controlled trials". International Journal of Surgery. 67: 37–46. doi:10.1016/j.ijsu.2019.05.003. PMID 31128316.
  2. ^ Belk JW, Kraeutler MJ, Houck DA, Goodrich JA, Dragoo JL, McCarty EC (January 2021). "Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials". The American Journal of Sports Medicine. 49 (1): 249–260. doi:10.1177/0363546520909397. PMID 32302218. S2CID 215809299.
  3. ^ a b c Hurley ET, Hannon CP, Pauzenberger L, Fat DL, Moran CJ, Mullett H (May 2019). "Nonoperative Treatment of Rotator Cuff Disease With Platelet-Rich Plasma: A Systematic Review of Randomized Controlled Trials". Arthroscopy. 35 (5): 1584–1591. doi:10.1016/j.arthro.2018.10.115. PMID 31000394. S2CID 122575307.
  4. ^ Smith PA (April 2016). "Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial". The American Journal of Sports Medicine. 44 (4): 884–891. doi:10.1177/0363546515624678. PMID 26831629. S2CID 42338794.
  5. ^ de la Portilla F, Segura-Sampedro JJ, Reyes-Díaz ML, Maestre MV, Cabrera AM, Jimenez-Rodríguez RM, et al. (November 2017). "Treatment of transsphincteric fistula-in-ano with growth factors from autologous platelets: results of a phase II clinical trial". International Journal of Colorectal Disease. 32 (11): 1545–1550. doi:10.1007/s00384-017-2866-9. PMID 28755243. S2CID 23285036.
  6. ^ a b c Alves R, Grimalt R (January 2018). "A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification". Skin Appendage Disorders. 4 (1): 18–24. doi:10.1159/000477353. PMC 5806188. PMID 29457008.
  7. ^ a b Pavlovic V, Ciric M, Jovanovic V, Stojanovic P (2016). "Platelet Rich Plasma: a short overview of certain bioactive components". Open Medicine. 11 (1): 242–247. doi:10.1515/med-2016-0048. PMC 5329835. PMID 28352802.
  8. ^ Lang S, Loibl M, Herrmann M (2018). "Platelet-Rich Plasma in Tissue Engineering: Hype and Hope". European Surgical Research. 59 (3–4): 265–275. doi:10.1159/000492415. PMID 30244245. S2CID 52344177.
  9. ^ Mohammed W, Farah S, Nassiri M, McKenna J (2020). "Therapeutic efficacy of platelet-rich plasma injection compared to corticosteroid injection in plantar fasciitis: A systematic review and meta-analysis". Journal of Orthopaedics. 22: 124–134. doi:10.1016/j.jor.2020.03.053. PMC 7177161. PMID 32336895.
  10. ^ Lin MT, Wei KC, Wu CH (March 2020). "Effectiveness of Platelet-Rich Plasma Injection in Rotator Cuff Tendinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Diagnostics. 10 (4): 189. doi:10.3390/diagnostics10040189. PMC 7235747. PMID 32231127.
  11. ^ Mishra A, Woodall J, Vieira A (January 2009). "Treatment of tendon and muscle using platelet-rich plasma". Clinics in Sports Medicine. 28 (1): 113–125. doi:10.1016/j.csm.2008.08.007. PMID 19064169.
  12. ^ Andia I, Sánchez M, Maffulli N (January 2012). "Joint pathology and platelet-rich plasma therapies". Expert Opinion on Biological Therapy. 12 (1): 7–22. doi:10.1517/14712598.2012.632765. PMID 22171664. S2CID 39322743.
  13. ^ Esposito M, Grusovin MG, Rees J, Karasoulos D, Felice P, Alissa R, et al. (Spring 2010). "Effectiveness of sinus lift procedures for dental implant rehabilitation: a Cochrane systematic review". European Journal of Oral Implantology. 3 (1): 7–26. PMID 20467595.
  14. ^ Por YC, Shi L, Samuel M, Song C, Yeow VK (May 2009). "Use of tissue sealants in face-lifts: a metaanalysis". Aesthetic Plastic Surgery. 33 (3): 336–339. doi:10.1007/s00266-008-9280-1. PMID 19089492. S2CID 26761928.
  15. ^ Annaniemi JA, Pere J, Giordano S (December 2022). "Platelet-Rich Plasma Injections Decrease the Need for Any Surgical Procedure for Chronic Epicondylitis versus Conservative Treatment-A Comparative Study with Long-Term Follow-Up". Journal of Clinical Medicine. 12 (1): 102. doi:10.3390/jcm12010102. PMC 9821066. PMID 36614903.
  16. ^ Dejnek M, Moreira H, Płaczkowska S, Barg E, Reichert P, Królikowska A (June 2022). "Effectiveness of Lateral Elbow Tendinopathy Treatment Depends on the Content of Biologically Active Compounds in Autologous Platelet-Rich Plasma". Journal of Clinical Medicine. 11 (13): 3687. doi:10.3390/jcm11133687. PMC 9267331. PMID 35806972.
  17. ^ Paramanantham M, Seenappa H, Venkataraman S, Shanthappa AH (March 2022). "Functional Outcome of Platelet-Rich Plasma (PRP) Intra-lesional Injection for Tennis Elbow - A Prospective Cohort Study". Cureus. 14 (3): e22974. doi:10.7759/cureus.22974. PMC 8990042. PMID 35415041.
  18. ^ a b Karjalainen TV, Silagy M, O'Bryan E, Johnston RV, Cyril S, Buchbinder R (September 2021). "Autologous blood and platelet-rich plasma injection therapy for lateral elbow pain". The Cochrane Database of Systematic Reviews. 2021 (9): CD010951. doi:10.1002/14651858.CD010951.pub2. PMC 8481072. PMID 34590307.
  19. ^ a b Chen X, Jones IA, Park C, Vangsness CT (July 2018). "The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias Assessment". The American Journal of Sports Medicine. 46 (8): 2020–2032. doi:10.1177/0363546517743746. PMC 6339617. PMID 29268037.
  20. ^ Klifto KM, Colbert SH, Richard MJ, Anakwenze OA, Ruch DS, Klifto CS (May 2022). "Platelet-rich plasma vs. corticosteroid injections for the treatment of recalcitrant lateral epicondylitis: a cost-effectiveness Markov decision analysis". Journal of Shoulder and Elbow Surgery. 31 (5): 991–1004. doi:10.1016/j.jse.2021.12.010. PMID 35031496. S2CID 245900117.
  21. ^ Kemp JA, Olson MA, Tao MA, Burcal CJ (June 2021). "Platelet-Rich Plasma versus Corticosteroid Injection for the Treatment of Lateral Epicondylitis: A Systematic Review of Systematic Reviews". International Journal of Sports Physical Therapy. 16 (3): 597–605. doi:10.26603/001c.24148. PMC 8169032. PMID 34123513.
  22. ^ Li A, Wang H, Yu Z, Zhang G, Feng S, Liu L, et al. (December 2019). "Platelet-rich plasma vs corticosteroids for elbow epicondylitis: A systematic review and meta-analysis". Medicine. 98 (51): e18358. doi:10.1097/MD.0000000000018358. PMC 6940118. PMID 31860992.
  23. ^ Houck DA, Kraeutler MJ, Thornton LB, McCarty EC, Bravman JT (March 2019). "Treatment of Lateral Epicondylitis With Autologous Blood, Platelet-Rich Plasma, or Corticosteroid Injections: A Systematic Review of Overlapping Meta-analyses". Orthopaedic Journal of Sports Medicine. 7 (3): 2325967119831052. doi:10.1177/2325967119831052. PMC 6419259. PMID 30899764.
  24. ^ Arirachakaran A, Sukthuayat A, Sisayanarane T, Laoratanavoraphong S, Kanchanatawan W, Kongtharvonskul J (June 2016). "Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: systematic review and network meta-analysis". Journal of Orthopaedics and Traumatology. 17 (2): 101–112. doi:10.1007/s10195-015-0376-5. PMC 4882297. PMID 26362783.
  25. ^ Hardy R, Tori A, Fuchs H, Larson T, Brand J, Monroe E (November 2021). "To Improve Pain and Function, Platelet-Rich Plasma Injections May Be an Alternative to Surgery for Treating Lateral Epicondylitis: A Systematic Review". Arthroscopy. 37 (11): 3360–3367. doi:10.1016/j.arthro.2021.04.043. PMID 33957212. S2CID 233982749.
  26. ^ Kim CH, Park YB, Lee JS, Jung HS (February 2022). "Platelet-rich plasma injection vs. operative treatment for lateral elbow tendinosis: a systematic review and meta-analysis". Journal of Shoulder and Elbow Surgery. 31 (2): 428–436. doi:10.1016/j.jse.2021.09.008. PMID 34656779. S2CID 239019467.
  27. ^ Boden AL, Scott MT, Dalwadi PP, Mautner K, Mason RA, Gottschalk MB (January 2019). "Platelet-rich plasma versus Tenex in the treatment of medial and lateral epicondylitis". Journal of Shoulder and Elbow Surgery. 28 (1): 112–119. doi:10.1016/j.jse.2018.08.032. PMID 30551782. S2CID 54632733.
  28. ^ Zhu P, Wang Z, Li H, Cai Y (September 2022). "Platelet-Rich Plasma Injection in Non-Operative Treatment of Partial-Thickness Rotator Cuff Tears: A Systematic Review and Meta-Analysis". Journal of Rehabilitation Medicine. 54: jrm00312. doi:10.2340/jrm.v54.1434. PMC 9495266. PMID 35892292.
  29. ^ Prodromos CC, Finkle S, Prodromos A, Chen JL, Schwartz A, Wathen L (May 2021). "Treatment of Rotator Cuff Tears with platelet rich plasma: a prospective study with 2 year follow-up". BMC Musculoskeletal Disorders. 22 (1): 499. doi:10.1186/s12891-021-04288-4. PMC 8164813. PMID 34051761.
  30. ^ Xiang XN, Deng J, Liu Y, Yu X, Cheng B, He HC (December 2021). "Conservative treatment of partial-thickness rotator cuff tears and tendinopathy with platelet-rich plasma: A systematic review and meta-analysis". Clinical Rehabilitation. 35 (12): 1661–1673. doi:10.1177/02692155211011944. PMID 33896214. S2CID 229348580.
  31. ^ Kwong CA, Woodmass JM, Gusnowski EM, Bois AJ, Leblanc J, More KD, et al. (February 2021). "Platelet-Rich Plasma in Patients With Partial-Thickness Rotator Cuff Tears or Tendinopathy Leads to Significantly Improved Short-Term Pain Relief and Function Compared With Corticosteroid Injection: A Double-Blind Randomized Controlled Trial". Arthroscopy. 37 (2): 510–517. doi:10.1016/j.arthro.2020.10.037. PMID 33127554. S2CID 226217973.
  32. ^ Kim SJ, Kim EK, Kim SJ, Song DH (January 2018). "Effects of bone marrow aspirate concentrate and platelet-rich plasma on patients with partial tear of the rotator cuff tendon". Journal of Orthopaedic Surgery and Research. 13 (1): 1. doi:10.1186/s13018-017-0693-x. PMC 5753487. PMID 29298726.
  33. ^ Giovannetti de Sanctis E, Franceschetti E, De Dona F, Palumbo A, Paciotti M, Franceschi F (December 2020). "The Efficacy of Injections for Partial Rotator Cuff Tears: A Systematic Review". Journal of Clinical Medicine. 10 (1): 51. doi:10.3390/jcm10010051. PMC 7795404. PMID 33375716.
  34. ^ Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA (November 2009). "Platelet-rich plasma: from basic science to clinical applications". The American Journal of Sports Medicine. 37 (11): 2259–2272. doi:10.1177/0363546509349921. PMID 19875361. S2CID 5914979.
  35. ^ Dai WL, Zhou AG, Zhang H, Zhang J (March 2017). "Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials". Arthroscopy. 33 (3): 659–670.e1. doi:10.1016/j.arthro.2016.09.024. PMID 28012636.
  36. ^ Shen L, Yuan T, Chen S, Xie X, Zhang C (January 2017). "The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials". Journal of Orthopaedic Surgery and Research. 12 (1): 16. doi:10.1186/s13018-017-0521-3. PMC 5260061. PMID 28115016.
  37. ^ Han Y, Huang H, Pan J, Lin J, Zeng L, Liang G, et al. (July 2019). "Meta-analysis Comparing Platelet-Rich Plasma vs Hyaluronic Acid Injection in Patients with Knee Osteoarthritis". Pain Medicine. 20 (7): 1418–1429. doi:10.1093/pm/pnz011. PMC 6611633. PMID 30849177.
  38. ^ Li V, Weng X (2022). "Platelet-rich plasma use in meniscus repair treatment: A systematic review and meta-analysis of clinical studies". Journal of Orthopaedic Surgery and Research. 17 (1): 446. doi:10.1186/s13018-022-03293-0. PMC 9548158. PMID 36209223.
  39. ^ Del Fabbro M, Bortolin M, Taschieri S, Weinstein R (2013). "Is Platelet Concentrate Advantageous for the Surgical Treatment of Periodontal Diseases? A Systematic Review and Meta-Analysis". Journal of Periodontology. 84 (11): 1566–1579. doi:10.1902/jop.2013.120657 (inactive 1 December 2024). PMC 3683340. PMID 23327406.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
  40. ^ Griffin XL, Smith CM, Costa ML (February 2009). "The clinical use of platelet-rich plasma in the promotion of bone healing: a systematic review". Injury. 40 (2): 158–162. doi:10.1016/j.injury.2008.06.025. PMID 19084836.
  41. ^ Pocaterra A, Caruso S, Bernardi S, Scagnoli L, Continenza MA, Gatto R (August 2016). "Effectiveness of platelet-rich plasma as an adjunctive material to bone graft: a systematic review and meta-analysis of randomized controlled clinical trials". International Journal of Oral and Maxillofacial Surgery. 45 (8): 1027–1034. doi:10.1016/j.ijom.2016.02.012. PMID 26987695.
  42. ^ Franchini M, Cruciani M, Mengoli C, Marano G, Pupella S, Veropalumbo E, et al. (November 2018). "Efficacy of platelet-rich plasma as conservative treatment in orthopaedics: a systematic review and meta-analysis". Blood Transfusion = Trasfusione del Sangue. 16 (6): 502–513. doi:10.2450/2018.0111-18. PMC 6214820. PMID 30201082.
  43. ^ Zhang YJ, Xu SZ, Gu PC, Du JY, Cai YZ, Zhang C, et al. (August 2018). "Is Platelet-rich Plasma Injection Effective for Chronic Achilles Tendinopathy? A Meta-analysis". Clinical Orthopaedics and Related Research. 476 (8): 1633–1641. doi:10.1007/s11999.0000000000000258. PMC 6259774. PMID 29601383.
  44. ^ Liu CJ, Yu KL, Bai JB, Tian DH, Liu GL (April 2019). "Platelet-rich plasma injection for the treatment of chronic Achilles tendinopathy: A meta-analysis". Medicine. 98 (16): e15278. doi:10.1097/MD.0000000000015278. PMC 6494278. PMID 31008973.
  45. ^ Cruciani M, Franchini M, Mengoli C, Marano G, Pati I, Masiello F, et al. (November 2019). "Platelet-rich plasma for sports-related muscle, tendon and ligament injuries: an umbrella review". Blood Transfusion = Trasfusione del Sangue. 17 (6): 465–478. doi:10.2450/2019.0274-19. PMC 6917536. PMID 31846610.
  46. ^ Tejapira K, Yongpisarn T, Sakpuwadol N, Suchonwanit P (2022-11-24). "Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review". Frontiers in Medicine. 9. Frontiers Media SA: 1058431. doi:10.3389/fmed.2022.1058431. PMC 9731377. PMID 36507528.
  47. ^ Gentile P, Garcovich S (April 2020). "Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy". International Journal of Molecular Sciences. 21 (8). MDPI AG: 2702. doi:10.3390/ijms21082702. PMC 7216252. PMID 32295047.
  48. ^ Evans AG, Mwangi JM, Pope RW, Ivanic MG, Botros MA, Glassman GE, et al. (February 2022). "Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis". The Journal of Dermatological Treatment. 33 (1). Informa UK Limited: 498–511. doi:10.1080/09546634.2020.1770171. PMID 32410524. S2CID 218648227.
  49. ^ Gupta AK, Cole J, Deutsch DP, Everts PA, Niedbalski RP, Panchaprateep R, et al. (October 2019). "Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia". Dermatologic Surgery. 45 (10). Ovid Technologies (Wolters Kluwer Health): 1262–1273. doi:10.1097/dss.0000000000001894. PMID 30882509. S2CID 81980415.
  50. ^ Gupta AK, Bamimore M (September 2022). "Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study". Journal of Drugs in Dermatology. 21 (9). SanovaWorks: 943–952. doi:10.36849/jdd.6948. PMID 36074501. S2CID 252120370.
  51. ^ Dogra Y, Singh N, Vanamail P (January 2022). "Autologous platelet-rich plasma optimizes endometrial thickness and pregnancy outcomes in women with refractory thin endometrium of varied aetiology during fresh and frozen-thawed embryo transfer cycles". JBRA Assisted Reproduction. 26 (1): 13–21. doi:10.5935/1518-0557.20210037. PMC 8769175. PMID 34296832.
  52. ^ Aghajanova L, Cedars MI, Huddleston HG (May 2018). "Platelet-rich plasma in the management of Asherman syndrome: case report". Journal of Assisted Reproduction and Genetics. 35 (5): 771–775. doi:10.1007/s10815-018-1135-3. PMC 5984883. PMID 29455274.
  53. ^ a b c Fraidakis M, Giannakakis G, Anifantaki A, Skouradaki M, Tsakoumi P, Bitzopoulou P, et al. (May 2023). "Intraovarian Platelet-Rich Plasma Injections: Safety and Thoughts on Efficacy Based on a Single Centre Experience With 469 Women". Cureus. 15 (5): e38674. doi:10.7759/cureus.38674. PMC 10243509. PMID 37288228.
  54. ^ Vaidakis D, Papapanou M, Siristatidis CS (April 2024). "Autologous platelet-rich plasma for assisted reproduction". The Cochrane Database of Systematic Reviews. 2024 (4): CD013875. doi:10.1002/14651858.CD013875.pub2. PMC 11057220. PMID 38682756.
  55. ^ Maged AM, Mohsen RA, Salah N, Ragab WS (January 2024). "The value of intraovarian autologous platelet rich plasma in women with poor ovarian reserve or ovarian insufficiency: a systematic review and meta-analysis". BMC Pregnancy and Childbirth. 24 (1): 85. doi:10.1186/s12884-024-06251-2. PMC 10821562. PMID 38280991.
  56. ^ "Venous Ulcer Symptoms and Treatment | UPMC". UPMC | Life Changing Medicine. Retrieved 2024-04-25.
  57. ^ Hu Z, Wang S, Yang H, Xv H, Shan B, Lin L, et al. (February 2024). "Efficacy and safety of platelet-rich plasma in the treatment of venous ulcers: A systematic review and meta-analysis of randomized controlled trials". International Wound Journal. 21 (2): e14736. doi:10.1111/iwj.14736. PMC 10869651. PMID 38361238.
  58. ^ Ruiz-Muñoz M, Martinez-Barrios FJ, Fernandez-Torres R, Lopezosa-Reca E, Marchena-Rodriguez A (February 2024). "Autologous platelet-rich plasma (APRP) in diabetes foot disease: a meta-analysis". Journal of Diabetes and Its Complications. 38 (2): 108690. doi:10.1016/j.jdiacomp.2024.108690. hdl:10630/29456. PMID 38278034.
  59. ^ "Platelet Rich Plasma". bcam.ac.uk. Retrieved 17 July 2024.
  60. ^ Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC (April 2014). "Platelet-rich therapies for musculoskeletal soft tissue injuries". The Cochrane Database of Systematic Reviews. 2014 (4): CD010071. doi:10.1002/14651858.CD010071.pub3. PMC 6464921. PMID 24782334.
  61. ^ Bielecki T, Dohan Ehrenfest DM, Everts PA, Wiczkowski A (June 2012). "The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives". Current Pharmaceutical Biotechnology. 13 (7): 1153–1162. doi:10.2174/138920112800624373. PMID 21740376.
  62. ^ a b c d Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F (October 2010). "Platelet-rich plasma in muscle healing". American Journal of Physical Medicine & Rehabilitation. 89 (10): 854–861. doi:10.1097/PHM.0b013e3181f1c1c7. PMID 20855985.
  63. ^ Yu W, Wang J, Yin J (April 2011). "Platelet-rich plasma: a promising product for treatment of peripheral nerve regeneration after nerve injury". The International Journal of Neuroscience. 121 (4): 176–180. doi:10.3109/00207454.2010.544432. PMID 21244302. S2CID 26837842.
  64. ^ Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, et al. (July 1998). "Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation". Thrombosis and Haemostasis. 80 (1): 171–175. doi:10.1055/s-0037-1615158. PMID 9684805. S2CID 795299.
  65. ^ Custo S, Baron B, Felice A, Seria E (5 July 2022). "A comparative profile of total protein and six angiogenically-active growth factors in three platelet products". GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW. 11 (Doc06): Doc06. doi:10.3205/iprs000167. PMC 9284722. PMID 35909816.
  66. ^ a b Dhurat R, Sukesh M (2014). "Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective". Journal of Cutaneous and Aesthetic Surgery. 7 (4): 189–197. doi:10.4103/0974-2077.150734. PMC 4338460. PMID 25722595.
  67. ^ Kanchanatawan W, Arirachakaran A, Chaijenkij K, Prasathaporn N, Boonard M, Piyapittayanun P, et al. (May 2016). "Short-term outcomes of platelet-rich plasma injection for treatment of osteoarthritis of the knee". Knee Surgery, Sports Traumatology, Arthroscopy. 24 (5): 1665–1677. doi:10.1007/s00167-015-3784-4. PMID 26387122. S2CID 35221300.
  68. ^ Beitzel K, Allen D, Apostolakos J, Russell RP, McCarthy MB, Gallo GJ, et al. (February 2015). "US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine". The Journal of Knee Surgery. 28 (1): 29–34. doi:10.1055/s-0034-1390030. PMID 25268794.
  69. ^ Schwarz A (2009-02-16). "A Promising Treatment for Athletes, in Blood". The New York Times. New York.
  70. ^ Kolata G (2010-01-12). "Popular Blood Therapy May Not Work". The New York Times.
  71. ^ Reynolds G (2011-01-26). "Phys Ed: Does Platelet-Rich Plasma Therapy Really Work?". The New York Times.
  72. ^ Storrs C (2009-12-18). "Is Platelet-Rich Plasma an Effective Healing Therapy?". Scientific American.
  73. ^ Georgiou A (14 September 2018). "What is a vampire facial?". Newsweek. Retrieved 29 March 2019.
  74. ^ "What it's really like to get the infamous vampire facial". The Independent. 28 February 2018. Retrieved 29 March 2019.
  75. ^ St John A (2024-04-29). "'Vampire facials' were linked to cases of HIV. Here's what to know about the beauty treatment". Associated Press. Retrieved 2024-04-29.
  76. ^ "O Shot in San Diego". The Independent. 28 February 2023. Retrieved 17 January 2023.
  77. ^ a b Osborne H (8 July 2016). "Injecting blood plasma into your clitoris for $2,500 won't give you with better orgasms". International Business Times UK. Retrieved 1 October 2018.
  78. ^ Goodman MP (2016). Female Genital Plastic and Cosmetic Surgery. John Wiley & Sons. p. PT391. ISBN 978-1-118-84848-7. There is presently no information in peer reviewed literature.
  79. ^ "World Anti-Doping Agency announces changes to Prohibited List". Irish Medical Times. 2011-01-10.
  80. ^ Mościcka P, Przylipiak A (September 2021). "History of autologous platelet-rich plasma: A short review". Journal of Cosmetic Dermatology. 20 (9). Wiley: 2712–2714. doi:10.1111/jocd.14326. PMC 9291029. PMID 34214233.
  81. ^ Ferrari M, Zia S, Valbonesi M, Henriquet F, Venere G, Spagnolo S, Grasso MA, Panzani I. A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 1987 Jan;10(1):47-50. PMID 3570542
Retrieved from "https://en.wiki.x.io/w/index.php?title=Platelet-rich_plasma&oldid=1260655385"